Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...374375376377378379380381382383384...10671068»
  • ||||||||||  isoxsuprine / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses (clinicaltrials.gov) -  Feb 1, 2022   
    P1/2,  N=2, Completed, 
    Sex, age at onset, and therapeutic intervals may influence the efficacy of IVMP in patients with NMO-ON. Recruiting --> Completed | N=20 --> 2 | Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Jun 2020 --> Jul 2021
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Sex differences in the genetic regulation of the blood transcriptome response to glucocorticoid receptor activation. (Pubmed Central) -  Feb 1, 2022   
    Gene expression levels in peripheral blood were obtained before and after GR-stimulation with the selective GR agonist dexamethasone to identify differential expression following GR-activation...Finally, transcriptional sensitive genetic profile scores derived from sex-stratified eSNPS regulating differential transcription to GR-stimulation were predictive of depression status and depressive symptoms in a sex-concordant manner in a child and adolescent cohort (n = 584). These results suggest the potential of eQTLs regulating differential transcription to GR-stimulation as biomarkers of sex-specific biological risk for stress-related psychiatric disorders.
  • ||||||||||  dexamethasone / Generic mfg., paclitaxel / Generic mfg.
    Journal:  RAPIDLY PROGRESSING PARAPARESIS AND LOSS OF SENSATION BELOW T10 DURING NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER (Pubmed Central) -  Feb 1, 2022   
    She was treated with neoadjuvant chemotherapy with dose dense adriamycin and cyclophosphamide followed by paclitaxel...High dose dexamethasone was promptly initiated and the patient was urgently planned for radiotherapy and received the first fraction of 3 Gy to level T11-S1...Two months after the initial diagnosis, she had a near complete resolution of her neurological deficits. This case illustrates both the tendency to ascribe new symptoms and clinical findings in cancer patients to progressive disease, and the importance of keeping a wide differential diagnosis for non-cancer etiologies when treating our patients.
  • ||||||||||  dexamethasone / Generic mfg., sirolimus / Generic mfg.
    Journal:  The 492nd case: recurrent thrombosis, thrombocytopenia (Pubmed Central) -  Feb 1, 2022   
    Platelet count elevated to normal after high dose glucocorticoid and intravenous immunoglobulin (IVIG)...When 4 grade thrombocytopenia recurred, intravenous heparin, rituximab 600 mg, IVIG and eltrombopag were administrated...Dexamethasone 20 mg/day × 4 days combined with sirolimus 2 mg/day was prescribed...At one month, her headache was greatly relieved. The platelet count raised to 20-30×10/L, and no new thrombosis or bleeding was reported.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Core clock regulators in dexamethasone-treated HEK 293T cells at 4 h intervals. (Pubmed Central) -  Feb 1, 2022   
    We synchronise a cell line of human origin with DEX to be used for studies on circadian rhythms. We treat HEK 293T cells with DEX and describe the patterns of mRNA and proteins of core clock regulators, while making a clear point on how CLOCK is less than an ideal molecule to help monitor rhythms in this cell line.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Drug infused AlO-bioactive glass coatings toward the cure of orthopedic infection. (Pubmed Central) -  Feb 1, 2022   
    Osteoblast-like cells (MG-63) exhibited profound proliferation with no cytotoxic effects which was due to release of Dex drug-coated substrates. Thus, surface modification of Cp-Ti substrate with BG, BG-Al composites coatings loaded with Tet and Dex drug can be considered for post-operative orthopedic implant infection application.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Metabolics risk factors in a New Zealand glioblastoma cohort. (Pubmed Central) -  Feb 1, 2022   
    Patients who received a lower dexamethasone dose had significantly better survival outcomes (15.0 vs 5.0 months, P < .01)...This finding further strengthens the possibility that a metabolic pathogenesis may underpin GBM. However, prospective clinical trials are needed.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Comparative Effects of Sulforaphane and Allyl Isothiocyanate on 3T3-L1 Adipogenesis. (Pubmed Central) -  Feb 1, 2022   
    A mixture of insulin, dexamethasone, and 3-isobutyl-1-methylxanthine was used to establish a differentiation medium...These results suggested that sulforaphane may be a more potent adipocyte differentiation inhibitor than allyl isothiocyanate. Our results may provide insight into possible strategies for the prevention of obesity and related conditions.
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg., clarithromycin / Generic mfg.
    Trial primary completion date:  GEM-CLARIDEX: Ld vs BiRd (clinicaltrials.gov) -  Feb 1, 2022   
    P3,  N=286, Active, not recruiting, 
    No abstract available Trial primary completion date: May 2021 --> Oct 2024
  • ||||||||||  fluvoxamine / Generic mfg., budesonide / Generic mfg., fluoxetine / Generic mfg.
    Trial completion date, Trial primary completion date:  Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms (clinicaltrials.gov) -  Feb 1, 2022   
    P3,  N=4669, Recruiting, 
    Trial completion date: Feb 2027 --> Jun 2027 | Trial primary completion date: Jan 2022 --> Jul 2022 Trial completion date: Mar 2022 --> Nov 2023 | Trial primary completion date: Feb 2022 --> Oct 2023
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection (clinicaltrials.gov) -  Jan 31, 2022   
    P4,  N=102, Enrolling by invitation, 
    Trial primary completion date: Jan 2023 --> Apr 2021 Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
  • ||||||||||  Semdexa (dexamethasone) / Sorrento
    Trial completion:  Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (clinicaltrials.gov) -  Jan 31, 2022   
    P3,  N=401, Completed, 
    Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2023 Active, not recruiting --> Completed
  • ||||||||||  Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
    Trial completion date, Trial primary completion date, Adherence:  ADITION: Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions (clinicaltrials.gov) -  Jan 31, 2022   
    P=N/A,  N=1000, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
  • ||||||||||  Kineret (anakinra) / SOBI
    The cytokine horror: Kawasaki disease shock syndrome complicated with macrophage activation syndrome () -  Jan 30, 2022 - Abstract #BSR2022BSR_429;    
    The fever did not settle following standard therapy that included three doses of intravenous immunoglobulins 2g/kg, aspirin and low dose dexamethasone. We emphasise the importance of early recognition of refractory MAS in pediatric populations with rheumatic diseases and we suggest early initiation of cyclosporin as a rapid and effective treatment option in the poor resource settings where the ideal management with anakinra is beyond the realms of possibility.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    A case of refractory paediatric Cogan’s syndrome treated with tocilizumab () -  Jan 30, 2022 - Abstract #BSR2022BSR_425;    
    Evidence regarding treatment options in paediatric patients is lacking due to the rarity of the condition and consequent difficulty in arranging high-quality trials. This is the first case report of use of tocilizumab for Cogan’s syndrome in children, highlighting it as a well-tolerated and successful treatment modality.
  • ||||||||||  Covid- 19 infection as a trigger for immune inflammatory myositis () -  Jan 30, 2022 - Abstract #BSR2022BSR_336;    
    The development of myositis-specific antibodies post infection has previously been described. This case highlights the significant dysphagia and debility despite a normal CK and the need for a high index of suspicion.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    A young girl with myocardial infarction () -  Jan 30, 2022 - Abstract #BSR2022BSR_318;    
    Though rare, Takayasu’s arteritis should be considered in any adolescent female presenting with ischemic type symptoms and positive inflammatory response. High index of suspicion can lead to early imaging and aggressive immunosuppression that will reduce the morbidity and mortality of this disease.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    The triple M threat of check-point inhibitorsan emerging overlap syndrome. () -  Jan 30, 2022 - Abstract #BSR2022BSR_317;    
    With ICI reshaping the prognosis of several cancers and pembrolizumab gaining recent further approvals, we will increasingly encounter this therapeutic challenge. Therefore, raising awareness of this overlap syndrome amongst rheumatologists is even more critical to allow for prompt recognition and treatment with immunosuppression.